Sanofi to Acquire Ablynx for $4.8B

Sanofi has agreed to acquire Ablynx for €3.9 billion ($4.8 billion) in a deal designed to expand the buyer’s R&D pipeline and rare blood disorders portfolio with a late-stage candidate and its underlying technology based on therapeutic proteins, or Nanobodies ® .The deal marks Sanofi’s second multi-billion-dollar acquisition of a rare-blood disorder drug developer in as many weeks, and third move to expand in blood treatments in three weeks.On January 22, Sanofi announce